GLSI_OUT_1 [2025-04-02 08:09:57 -0400] 2950 Bytes | 764 tokens | Cum: 764 tkns (9.55% of 8k)
==========================================================================

Alright, let’s light it up, because it's 8:09:57 AM on Wed Apr 02, 2025 -0400, and I'm charging into Greenwich LifeSciences (GLSI), popping from 9.26 to 11.2. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Greenwich LifeSciences (GLSI)
IPO: 2020-09-25 (4 Years Ago)
Market Cap: $121,719,487
Shares Outstanding: 13,150,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.

Here's the first list of news for Greenwich LifeSciences:

C1 - Today 06:00AM - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
C2 - Mar-27-25 06:00AM - Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
C3 - Mar-17-25 06:45AM - Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
C4 - Feb-10-25 06:00AM - Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
C5 - Jan-30-25 11:13AM - EMA approves addition of sites to Greenwich LifeSciences breast cancer trial
C6 - Jan-29-25 06:00AM - Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
C7 - Jan-27-25 06:00AM - Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
C8 - Jan-23-25 06:00AM - Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Greenwich LifeSciences (GLSI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GLSI_OUT_3 [2025-04-02 08:09:58 -0400] 1099 Bytes | 331 tokens | Cum: 1097 tkns (13.71% of 8k)
==========================================================================

Showing C1 (chunk 1 of 11): C1:
**Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial**
Date: Today 06:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054058/0/en/Greenwich-LifeSciences-Announces-Positive-Immune-Response-Data-from-FLAMINGO-01-Phase-III-Clinical-Trial.html

April 02, 2025 06:00 ET| Source:Greenwich LifeSciences, Inc.Greenwich LifeSciences, Inc.

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data.

The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLSI_OUT_5 [2025-04-02 08:09:59 -0400] 1017 Bytes | 296 tokens | Cum: 1395 tkns (17.44% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T10:52:07Z - Greenwich LifeSciences (GLSI) Announces Positive Immune Response Data from FLAMINGO-01 Phase III Cli...
A2 - 2025-04-02T10:35:36Z - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical T...
A3 - 2025-04-02T10:11:01Z - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical T...
A4 - 2025-04-02T10:09:00Z - Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical T...
A5 - 2025-04-02T04:58:09Z - Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7% - Here's What Happened...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GLSI_OUT_7 [2025-04-02 08:10:02 -0400] 944 Bytes | 279 tokens | Cum: 1676 tkns (20.95% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
**Greenwich LifeSciences (GLSI) Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial**Date: 2025-04-02Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/FDA/Greenwich+LifeSciences+%28GLSI%29+Announces+Positive+Immune+Response+Data+from+FLAMINGO-01+Phase+III+Clinical+Trial/24586308.htmlGreenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLSI_OUT_9 [2025-04-02 08:10:02 -0400] 836 Bytes | 259 tokens | Cum: 1999 tkns (24.99% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-27T10:00:00Z - Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
B2 - 2025-01-27T11:00:00Z - Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
B3 - 2025-01-22T11:00:00Z - Greenwich LifeSciences Provides Update on Commercial Manufacturing
B4 - 2024-11-18T11:00:00Z - Greenwich LifeSciences Provides Update on Corporate Events
B5 - 2024-06-26T11:33:00Z - Greenwich LifeSciences Set to Join Russell 2000 Index Again
B6 - 2024-06-14T10:00:00Z - Greenwich LifeSciences Announces $2.5 Million Private Placement

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLSI_OUT_11 [2025-04-02 08:10:09 -0400] 820 Bytes | 228 tokens | Cum: 2229 tkns (27.86% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/27/3050341/0/en/Greenwich-LifeSciences-Extends-Lock-up-of-Directors-and-Officers-to-March-31-2026.htmlGreenwich LifeSciences, a clinical-stage biopharmaceutical company, announced that its Board of Directors has extended the lock-up of shares owned by directors, officers, and existing pre-IPO investors to March 31, 2026. This move aims to restrict the sale of these shares during this period, unless otherwise modified by the Board.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

GLSI_OUT_13 [2025-04-02 08:10:09 -0400] 1056 Bytes | 351 tokens | Cum: 2714 tkns (33.92% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2024-11-14 10-Q PART I. FIN INFO

ITEM 1. COND FIN STATEMENTS

GREENWICH LIFESCIENCES, INC.

COND BAL SHEETS

AS OF SEPTEMBER 30, 2024 & DECEMBER 31, 2023 (UNAUDITED)

September 30,

December 31,

Assets Curr assets Cash $ 5,822,367 $ 6,989,424 Acqu...

S5 - 2024-08-14 10-Q PART I. FIN INFO

ITEM 1. COND FIN STATEMENTS

GREENWICH LIFESCIENCES, INC.

COND BAL SHEETS

AS OF JUNE 30, 2024 & DECEMBER 31, 2023 (UNAUDITED)

June 30, 2024 December 31, 2023 Assets Curr assets Cash $ 7,224,875 $ 6,989,424 Acquired...

S6 - 2024-06-17 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On June 13, 2024, Greenwich LifeSciences, Inc. (the Company ) entered into a securities purchase agreement (the Purchase Agrmt ) with Snehal Patel, its Chf Exec Off, pursuant to which the Company agreed to iss...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GLSI_OUT_15 [2025-04-02 08:10:18 -0400] 4561 Bytes | 1337 tokens | Cum: 4054 tkns (50.68% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+---------------------+
| Volume: 87,906 | Perf Month: -20.85% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+------------------------+---------------------+
| Avg Volume: 33.91K | Perf Quarter: -19.48% | Short Float: 11.14% | ROE: -151.72% |
+--------------------+-----------------------+------------------------+---------------------+
| Rel Volume: 2.66 | Index: RUT | Short Ratio: 19.42 | ROI: -210.64% |
+--------------------+-----------------------+------------------------+---------------------+
| RSI (14): 22.41 | Market Cap: 121.72M | Short Interest: 0.66M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+---------------------+
| ATR (14): 0.65 | Shs Outstand: 13.14M | Beta: 3.39 | EPS Surprise: 0.00% |
+--------------------+-----------------------+------------------------+---------------------+
| SMA20: -17.58% | Shs Float: 5.91M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+------------------------+---------------------+
| SMA50: -22.49% | Inst Own: 8.94% | Sales past 5Y: - | Earnings: Feb 26 |
+--------------------+-----------------------+------------------------+---------------------+
| SMA200: -31.88% | Insider Own: 55.06% | Employees: - | |
+--------------------+-----------------------+------------------------+---------------------+
| Perf Week: -13.05% | Insider Trans: 0.24% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+------------------------+---------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Greenwich LifeSciences, Inc. (GLSI) by Patel Snehal (CEO and CFO) on 2025-01-10
- Common Stock: 2500 shares at $12.51 (D)

Inside Trans: Greenwich LifeSciences, Inc. (GLSI) by Patel Snehal (CEO and CFO) on 2025-01-06
- Common Stock: 1100 shares at $13.31 (D)
- Common Stock: 1800 shares at $13.75 (D)

Inside Trans: Greenwich LifeSciences, Inc. (GLSI) by Patel Snehal (CEO and CFO) on 2025-01-03
- Common Stock: 3400 shares at $12.95 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -10495329.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 9.26
Average Volume: 37925.55
30-Day High: 12.21
30-Day Low: 9.26

[Detailed Financials: Q3 2024]
- Total Assets: $5,825,049.0
- Total Liabilities: $842,384
- Total Equity: $4,982,665.0
- Current Assets: $5,825,049.0
- Current Liabilities: $842,384

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-2,583,932.0

[Detailed Financials: Q2 2024]
- Total Assets: $7,228,460.0
- Total Liabilities: $1,353,028.0
- Total Equity: $5,875,432.0
- Current Assets: $7,228,460.0
- Current Liabilities: $1,353,028.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.2

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-1,047,840.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

GLSI_OUT_17 [2025-04-02 08:10:19 -0400] 676 Bytes | 167 tokens | Cum: 4434 tkns (55.43% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GLSI_IN_19 [2025-04-02 08:10:19 -0400] 126 Bytes | 29 tokens | Cum: 4491 tkns (56.14% of 8k)
==========================================================================

====================================
[2025-04-02 08:10:19] # Analysis Completed
Elapsed Time: 22.90 seconds